Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

NCT03523975 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03523975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03523975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Multi-site Study Evaluating the MTD, Safety and Efficacy of the Combination Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Lead sponsor
City of Hope Medical Center
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 28, 2018
Completion date
June 24, 2027
Enrollment
28 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma